Responses
Regular and young investigator award abstracts
Clinical trials in progress
369 Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.
